hemophagocytic lymphohistiocytosis
Conditions
Interventions
Intervention group:Ruxolitinib combined with the reduced-dose LH-1994 regimen for the induction therapy of adult hemophagocytic lymphohistiocytosis
Sponsors
Shandong Provincial Qianfoshan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Age >=18 years; 2.The patient has not received HLH treatment and was in an active state of HLH at the time of enrollment; 3.Patients who received glucocorticoid treatment before enrollment but still had active HLH after assessment could be included in this study (the dosage of glucocorticoids in the previous period should be noted at the time of enrollment). 4.For HLH secondary to rheumatic immune diseases, those who have no response after one week of glucocorticoid treatment; 5.The patient signed the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Patients with definite active infections, such as leishmania, brucellosis, histoplasmosis, fungal infections or other uncontrollable bacterial infections, or HIV-infected individuals; 2.Patients with severe central nervous system involvement; 3.Patients with active massive hemorrhage of internal organs (including massive hemorrhage of the digestive tract, intracranial hemorrhage, alveolar hemorrhage, etc.); 4.Patients participating in other clinical studies at the same time; 5.Patients cannot be followed up;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate;Overall response rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;1-year overall survival rate; | — |
Countries
China
Contacts
Public ContactGuangqiang Meng
Shandong Provincial Qianfoshan Hospital
Outcome results
None listed